Program
N-Methyl-3,4-methylenedioxyamphetamine
Also written as “Midomafetamine HCl”, “Midomafetamine” and “midomafetamine HCl”.
Its studies are mostly in Stress Disorders, Post-Traumatic · Autism Spectrum Disorder · Autistic Disorder · Anxiety Disorders · Binge-Eating Disorder, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Resilient Pharmaceuticals | 262 open or running | phase 3since May 14, 2018 | Aug 24, 2004 | Dec 2028phase 1 · NCT03606538 |
| Definium Therapeutics US | 10 open or running | phase 2since Dec 22, 2025 | Dec 22, 2025 | none ahead |
| MAPS Europe | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Remedy | 10 open or running | phase 2since Sep 19, 2021 | Sep 19, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Aug 24, 2004.
- May 14, 2018Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT03537014 · 100 enrolled · United States, Canada, Israel
- Jul 20, 2018Phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT03606538 · 16 planned · United States
- Jul 19, 2019MAPS Europe’s first study: phase 2 study in Stress Disorders, Post-TraumaticNew to MAPS EuropeMAPS Europe · NCT04030169 · 21 enrolled · Czechia, Germany, Netherlands and more
- Jul 30, 2019Phase 1 study in Psychological Effects of Study DrugResilient Pharmaceuticals · NCT04073433
- Aug 30, 2019Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04077437 · 121 enrolled · United States, Israel
- Jun 26, 2020Phase 2 study in Binge-Eating DisorderResilient Pharmaceuticals · NCT04454684
- Jan 14, 2021Phase 3 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04714359 · 87 enrolled · United States, Canada, Israel
- Mar 2, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04784143 · 26 enrolled · United States
- Jul 9, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT04968938
- Sep 19, 2021Remedy’s first study: phase 2 study in Stress Disorders, Post-TraumaticNew to RemedyRemedy · NCT05067244 · 10 enrolled · Canada
- Nov 24, 2021Phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT05147402 · 14 enrolled · United States
- Dec 13, 2021Phase 2 study in Stress Disorders, Post-TraumaticResilient Pharmaceuticals · NCT05173831
- Dec 22, 2025Definium Therapeutics US’s first study: phase 2 study in Autism Spectrum DisorderNew to Definium Therapeutics USDefinium Therapeutics US · NCT07303907 · 5 enrolled · United States
- Apr 30, 2026Phase 1 study in Healthy VolunteersResilient Pharmaceuticals · NCT07584720 · 32 enrolled · United States
Ahead
- Dec 2028Primary completion: phase 1 study in PharmacokineticsResilient Pharmaceuticals · NCT03606538
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07584720Healthy Volunteers · United States | 1 | Active, not recruiting | Resilient Pharmaceuticals | Jul 23, 2026 | 32 |
| NCT07303907Autism Spectrum Disorder · United States | 2 | Completed | Definium Therapeutics US | Sep 16, 2026 | 5 |
| NCT05173831Stress Disorders, Post-Traumatic | 2 | Withdrawn | Resilient Pharmaceuticals | Dec 2024 | 0 |
| NCT05147402Pharmacokinetics · United States | 1 | Completed | Resilient Pharmaceuticals | Dec 2, 2022 | 14 |
| NCT05067244Stress Disorders, Post-Traumatic · Canada | 2 | Completed | Remedy | Nov 1, 2024 | 10 |
| NCT04968938Stress Disorders, Post-Traumatic | 2 | Withdrawn | Resilient Pharmaceuticals | Aug 2023 | 0 |
| NCT04784143Stress Disorders, Post-Traumatic · United States | 2 | Terminated | Resilient Pharmaceuticals | Jun 25, 2024 | 26 |
| NCT04714359Stress Disorders, Post-Traumatic · United States, Canada, Israel | 3 | Completed | Resilient Pharmaceuticals | Nov 1, 2023 | 87 |
| NCT04454684Binge-Eating Disorder | 2 | Withdrawn | Resilient Pharmaceuticals | Aug 10, 2028 | 0 |
| NCT04077437Stress Disorders, Post-Traumatic · United States, Israel | 3 | Completed | Resilient Pharmaceuticals | Oct 30, 2022 | 121 |
| NCT04073433Psychological Effects of Study Drug | 1 | Withdrawn | Resilient Pharmaceuticals | Dec 2025 | 0 |
| NCT04030169Stress Disorders, Post-Traumatic · Czechia, Germany, Netherlands and more | 2 | Completed | MAPS Europe | Dec 14, 2023 | 21 |
| NCT03606538Pharmacokinetics · United States | 1 | Not yet recruiting | Resilient Pharmaceuticals | Dec 2028 | 16 |
| NCT03537014Stress Disorders, Post-Traumatic · United States, Canada, Israel | 3 | Completed | Resilient Pharmaceuticals | Aug 11, 2020 | 100 |
| NCT03485287Stress Disorders, Post-Traumatic · Canada | 2 | Completed | Resilient Pharmaceuticals | Jun 4, 2019 | 4 |
| NCT03282123Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | Aug 10, 2019 | 38 |
| NCT03181763Startle Response · United States | 1 | Completed | Resilient Pharmaceuticals | Aug 1, 2020 | 34 |
| NCT02876172Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | Dec 16, 2017 | 12 |
| NCT02427568Anxiety Disorders · United States | 2 | Completed | Resilient Pharmaceuticals | Apr 25, 2017 | 18 |
| NCT02008396Autistic Disorder · United States | 2 | Completed | Resilient Pharmaceuticals | Apr 28, 2017 | 12 |
| NCT01958593Stress Disorders, Post-Traumatic · Canada | 2 | Terminated | Resilient Pharmaceuticals | Sep 10, 2015 | 6 |
| NCT01793610Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | Dec 3, 2015 | 29 |
| NCT01689740Stress Disorders, Post-Traumatic · Israel | 2 | Completed | Resilient Pharmaceuticals | Apr 7, 2016 | 10 |
| NCT01458327Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | Jun 27, 2014 | 3 |
| NCT01404754Psychological Effects of Study Drug · United States | 1 | Completed | Resilient Pharmaceuticals | Aug 5, 2022 | 107 |
| NCT01211405Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | Jun 4, 2015 | 26 |
| NCT00402298Stress Disorders, Post-Traumatic · Israel | 2 | Terminated | Resilient Pharmaceuticals | Mar 2009 | 5 |
| NCT00353938Stress Disorders, Post-Traumatic · Switzerland | 2 | Completed | Resilient Pharmaceuticals | Sep 2, 2009 | 14 |
| NCT00090064Stress Disorders, Post-Traumatic · United States | 2 | Completed | Resilient Pharmaceuticals | May 2, 2008 | 23 |
How it is read
Names in the registry
- “Midomafetamine HCl”, 10 entries
- “Midomafetamine”, 7 entries
- “midomafetamine HCl”, 2 entries
- “MDMA”, 2 entries
- “midomafetamine”, 2 entries
Conditions, from the studies’ own filings
- Stress Disorders, Post-Traumatic, 19 studies
- Autism Spectrum Disorder, 1 study
- Autistic Disorder, 1 study
- Anxiety Disorders, 1 study
- Binge-Eating Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.